Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price hoisted by research analysts at JPMorgan Chase & Co. from $200.00 to $209.00 in a report released on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the specialty pharmaceutical company’s stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 43.42% from the company’s current price.

JAZZ has been the subject of several other reports. TD Cowen cut their target price on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research note on Thursday, November 7th. Robert W. Baird upped their target price on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research report on Monday, November 18th. Morgan Stanley upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $140.00 to $175.00 in a research report on Thursday, December 12th. Wells Fargo & Company upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $130.00 to $170.00 in a research report on Thursday, February 13th. Finally, HC Wainwright reiterated a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. One analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $181.00.

Jazz Pharmaceuticals Stock Performance

JAZZ stock traded up $6.06 during trading on Wednesday, reaching $145.73. The stock had a trading volume of 770,358 shares, compared to its average volume of 643,471. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The firm has a market cap of $8.81 billion, a PE ratio of 20.44, a PEG ratio of 1.04 and a beta of 0.56. The stock’s 50 day moving average is $125.42 and its two-hundred day moving average is $118.44. Jazz Pharmaceuticals has a 52 week low of $99.06 and a 52 week high of $145.44.

Insiders Place Their Bets

In other news, CEO Bruce C. Cozadd sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $121.17, for a total value of $242,340.00. Following the completion of the sale, the chief executive officer now directly owns 427,025 shares of the company’s stock, valued at approximately $51,742,619.25. This represents a 0.47 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold 5,053 shares of company stock valued at $617,442 over the last quarter. Insiders own 4.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Fuller & Thaler Asset Management Inc. grew its holdings in shares of Jazz Pharmaceuticals by 117.4% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 939,351 shares of the specialty pharmaceutical company’s stock worth $115,681,000 after purchasing an additional 507,234 shares in the last quarter. Darwin Global Management Ltd. bought a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at $59,668,000. Dimensional Fund Advisors LP raised its holdings in shares of Jazz Pharmaceuticals by 18.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company’s stock worth $250,619,000 after acquiring an additional 320,724 shares during the period. Ameriprise Financial Inc. boosted its holdings in Jazz Pharmaceuticals by 20.9% during the fourth quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company’s stock worth $225,076,000 after purchasing an additional 315,608 shares during the last quarter. Finally, GMT Capital Corp grew its position in shares of Jazz Pharmaceuticals by 140.0% in the 4th quarter. GMT Capital Corp now owns 508,800 shares of the specialty pharmaceutical company’s stock valued at $62,659,000 after acquiring an additional 296,800 shares during the period. Institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.